Exenatide, another GLP-1 receptor agonist, may be an available therapeutic agent also presently used in the treatment of diabetes or obesity, which might have additional and favorable effects on cognitive function in human patients [79]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.